Obermatt
See Similar Stocks →

ICON

NSQ:ICLR · IE0005711209
Life Sciences Tools & ServicesX-Large

360

47
EV / EBIT90
Price / Owner Earnings46
Owner Earnings Yield75
Dividend Yield1
Price/Sales78
EV / Gross Profit73
Price/Book67
Return on Capital51
Cash Return on Capital59
Return on Equity40
EBIT Margin47
Gross Profitability29
Cash Conversion91
Accruals69
Owner Earnings Margin53
Sales growth23
Profit Growth94
Long-Term EPS Growth19
Owner Earnings Growth11
Reinvestment43
Price momentum55
Debt load65
Refinancing65
Debt Payback28
Liquidity67
Analyst ratings17
Opinion Changes86
Price Target Upside17
Market mood79
Value Creation8/20creating some value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

ICON clears its cost of capital, but the record is mixed across the five tests. Real value creation, just not yet consistent.

Profile

CountryIreland
IndustryLife Sciences Tools & Services
SizeX-Large
TypePublic Company
ExchangeNASDAQGS
Founded1989
Employees32,396
Websiteiconplc.com
ISINIE0005711209
Last UpdateApr 2, 2026
Indices
NASDAQ (USA)
Themes
ImmunologyChronic DiseasesArtificial IntelligenceOncologyPredictive AnalyticsHealth DiagnosticsCardiovascularVaccinesCentral Nervous SystemInfectious DiseasesBiopharmaBiotechnologyMedicalPharmaceutical

Description

ICON Public Limited Company (ICON) is a global provider of outsourced development and commercialization services to pharmaceutical, biotechnology, medical device, and government and public health organizations. The company offers a full range of cli…

Analysis

Bargain bin

ICON Public Limited Company falls in the bargain bin: the price is low relative to peers, but the business metrics give reason to pause.

The price is expensive. You pay 25.2× its owner earnings: the cash an owner could take out each year, which is in the historically expensive zone. At today's price, the market is assuming roughly 9% yearly growth; analysts expect 5%. The gap between price and consensus is worth watching: demanding expectations.

The trajectory is tepid and the balance sheet is adequate. The company scores 8/20 on our value-creation score: creating some value.

What to watch: A large part of the company's book value is the price paid for past acquisitions. As always: this describes the company's numbers; it is not a recommendation.

360° rank · history

1007550250
98
2023202420252026

All-time high

98

Jun 2026

All-time low

9

Jan 2025

Average rank

59

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
78
53
38
39
Price/Earnings
34
38
28
25
Price/Book
67
58
34
65
Dividend Yield
1
1
1
1
Value (overall)
70
30
19
33

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare ICON with its peers
PolyPeptide
SWX:PPGN
37
CountryGuernsey
IndustryLife Sciences Tools & Services
SizeSmall
Full Stock Analysis →
Prothena Corporation
NSQ:PRTA
39
CountryIreland
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Innate Pharma
PAR:IPH
54
CountryFrance
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
MindMaze Therapeutics Holding
SWX:MMTX
49
CountrySwitzerland
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Valneva
PAR:VLA
21
CountryFrance
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Oxford Nanopore Technologies
LSE:ONT
23
CountryUK
IndustryLife Sciences Tools & Services
SizeSmall
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →